Synfacts 2019; 15(11): 1310
DOI: 10.1055/s-0039-1690282
Chemistry in Medicine and Biology
© Georg Thieme Verlag Stuttgart · New York

Pre-Exposure Prophylaxis (PrEP)

Contributor(s):
Dirk Trauner
,
Andrej Shemet
Liotta DC, Schinazi RF, Choi W.-B. Emery University, Atlanta, USA
Method for the Synthesis, Compositions and Use of 2′-Deoxy-5-fluoro-3′-thiacytidine and Related Compounds.

US Patent 5210085, 1993
Bischofberger NW. Gilead Sciences Inc., Foster City, USA
PMPA Preparation.

US Patent 5733788, 1998
Further Information

Publication History

Publication Date:
18 October 2019 (online)

 

Significance

Pre-exposure prophylaxis (PrEP) is a HIV prevention method for uninfected individuals. It virtually eliminates the risk of getting HIV if taken consistently and correctly. Truvada is the drug used for PrEP. It contains a combination of emtricitabine and tenofovir disoproxil fumarate (prodrug).


#

Comment

Emtricitabine was synthesized by nucleosidation of a readily available oxathiolane derivate with the silylated nucleobase B. The high level of stereoselectivity is provided by in situ complexation of the oxathiolane and the Lewis acid. Tenofovir was synthesized in just six steps starting from commercially available (S)-glycidol.


#
#